Association of Serotonin Transporter (SERT) Polymorphisms with Opioid Dependence and Dimensional Aspects of Cocaine Use in a Caucasian Cohort of Opioid Users.
KMSK scale
SLC6A4
cocaine
escalation
serotonin transporter
Journal
Neuropsychiatric disease and treatment
ISSN: 1176-6328
Titre abrégé: Neuropsychiatr Dis Treat
Pays: New Zealand
ID NLM: 101240304
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
10
2020
accepted:
25
12
2020
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
5
3
2021
Statut:
epublish
Résumé
A functional tandem repeat polymorphism in the promoter of the serotonin transporter (SERT) gene (SLC6A4) has been studied for association to neuropsychiatric conditions, including substance use disorders. Short (S) forms of this repeat result in reduced transcription, and presumably greater synaptic levels of serotonin, which are involved in opioid and cocaine-induced reward. Dual exposure to heroin and cocaine is a common pattern of poly-drug use and is associated with considerable morbidity. We hypothesize that SLC6A4 variants are associated with cocaine exposure in subjects with an opioid dependence diagnosis (OD), and also in non-dependent opioid users (NOD). Other single nucleotide polymorphisms (SNPs) of SLC6A4 may also be likewise associated. This study determined whether variants of the SLC6A4 promoter repeats and two intronic SNPs, rs16965628 and rs2066713, are associated with categorical diagnoses of opioid dependence (DSM-IV criteria) and with dimensional aspects of cocaine use, in a Caucasian cohort (n=591). Three groups of subjects were examined: (1) 276 subjects with opioid dependence diagnosis (OD); (2) 163 subjects who had used opioids for non-medical reasons but never had an opioid dependence diagnosis (NOD); (3) 152 healthy controls (HC). Aside from high exposure to heroin in the OD group, relatively high exposure to cocaine was detected in both OD and NOD groups. The SERT repeat genotype (classified as "long-long" [LL] versus "short-long" plus "short-short" [SL+SS]) was not associated with categorical opioid dependence diagnoses. A nominally significant association was identified with the [SL+SS] genotype of SLC6A4 and cocaine KMSK scores ≥"cutpoint" for a cocaine dependence diagnosis ( The functional SERT promoter tandem repeat genotype may be associated to heavy cocaine exposure and more rapid escalation of cocaine use, in persons with and without opioid dependence diagnosis.
Identifiants
pubmed: 33658787
doi: 10.2147/NDT.S286536
pii: 286536
pmc: PMC7920580
doi:
Types de publication
Journal Article
Langues
eng
Pagination
659-670Informations de copyright
© 2021 Yuferov et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Am J Public Health. 2017 Mar;107(3):430-432
pubmed: 28177817
Psychopharmacology (Berl). 2017 Aug;234(15):2219-2231
pubmed: 28550455
Am J Psychiatry. 1998 Feb;155(2):207-13
pubmed: 9464199
J Neurochem. 1996 Jun;66(6):2621-4
pubmed: 8632190
Transl Psychiatry. 2013 Sep 24;3:e307
pubmed: 24064711
Addict Biol. 2012 Jan;17(1):181-91
pubmed: 21070507
Biometrics. 1997 Dec;53(4):1253-61
pubmed: 9423247
Neuropharmacology. 2011 Sep;61(3):421-32
pubmed: 21466815
Exp Clin Psychopharmacol. 2005 Nov;13(4):303-10
pubmed: 16366760
Neuropharmacology. 2016 Jun;105:639-650
pubmed: 26777278
J Stud Alcohol Drugs. 2011 Sep;72(5):752-62
pubmed: 21906503
Am J Med Genet B Neuropsychiatr Genet. 2004 Apr 1;126B(1):37-42
pubmed: 15048645
Alcohol Clin Exp Res. 2014 Jun;38(6):1575-81
pubmed: 24796636
Biol Psychiatry. 2018 Jun 15;83(12):1024-1035
pubmed: 29357981
Curr Psychiatry Rep. 2006 Dec;8(6):452-7
pubmed: 17094925
J Pharmacol Exp Ther. 1998 Jul;286(1):481-8
pubmed: 9655893
Pharmacogenomics. 2015;16(11):1307-14
pubmed: 26265436
Science. 1996 Nov 29;274(5292):1527-31
pubmed: 8929413
Genes Brain Behav. 2008 Oct;7(7):720-9
pubmed: 18518925
Psychiatr Genet. 2017 Oct;27(5):178-186
pubmed: 28590957
Psychiatr Genet. 2002 Sep;12(3):161-4
pubmed: 12218660
Pharmacogenomics. 2018 Jan;19(2):95-104
pubmed: 29210332
J Chem Neuroanat. 2000 Dec;20(3-4):271-80
pubmed: 11207425
Am J Psychiatry. 2009 Sep;166(9):1031-40
pubmed: 19605534
Addict Biol. 2018 Jan;23(1):474-484
pubmed: 28150397
Hum Genet. 1997 Dec;101(2):243-6
pubmed: 9402979
Neuropsychopharmacology. 2013 Aug;38(9):1737-47
pubmed: 23518607
Pharmacogenomics. 2019 Apr;20(5):331-341
pubmed: 30983500
Nat Rev Genet. 2005 Jul;6(7):521-32
pubmed: 15995696
Drug Alcohol Depend. 2018 Sep 1;190:179-187
pubmed: 30041093
Hum Genet. 2014 Apr;133(4):459-61
pubmed: 24385047
Eur Neuropsychopharmacol. 2010 Apr;20 Suppl 2:S105-58
pubmed: 20362236
Psychiatry Res. 2013 Dec 30;210(3):1287-9
pubmed: 24120036
Hum Genomics. 2012 Jul 05;6:2
pubmed: 23244743
Pharmacogenomics. 2020 Aug;21(13):903-917
pubmed: 32757697
Eur J Neurosci. 2003 May;17(10):2212-8
pubmed: 12786988
BMC Psychiatry. 2011 May 05;11:76
pubmed: 21545724
Eur J Neurosci. 2013 Dec;38(12):3749-57
pubmed: 24118121
Hum Mol Genet. 2008 Mar 1;17(5):717-23
pubmed: 18055562
Psychiatr Clin North Am. 2012 Jun;35(2):495-519
pubmed: 22640768
Drug Alcohol Depend. 2019 Dec 1;205:107657
pubmed: 31698322
Psychopharmacology (Berl). 2020 Apr;237(4):1147-1160
pubmed: 31915862
Science. 1987 Sep 4;237(4819):1219-23
pubmed: 2820058
Psychopharmacology (Berl). 2004 Aug;175(1):26-36
pubmed: 15042275
Neuropsychiatr Dis Treat. 2018 Apr 16;14:1025-1034
pubmed: 29713172
Drug Alcohol Depend. 2014 Dec 1;145:101-5
pubmed: 25454407
Neuropharmacology. 2005 Oct;49(5):618-26
pubmed: 15936043
Am J Addict. 2011 May-Jun;20(3):292-9
pubmed: 21477058
Psychopharmacology (Berl). 2001 Aug;157(1):31-9
pubmed: 11512040
Pharmacology. 2007;80(2-3):65-119
pubmed: 17570954
Dig Liver Dis. 2010 Sep;42(9):650-6
pubmed: 20418192
Addict Biol. 2019 Nov;24(6):1167-1178
pubmed: 30144237
Drug Alcohol Depend. 2016 Nov 01;168:164-169
pubmed: 27664554
BMC Pharmacol. 2006 Mar 03;6:6
pubmed: 16515684
Int J Drug Policy. 2017 Nov;49:32-40
pubmed: 28888099
Neuropsychiatr Dis Treat. 2016 Nov 30;12:3061-3067
pubmed: 27942217
Drug Alcohol Depend. 2003 Mar 1;69(2):137-50
pubmed: 12609695
Neurosci Lett. 2019 Jun 21;704:100-105
pubmed: 30936032
Neurosci Biobehav Rev. 2004 Jan;27(8):739-49
pubmed: 15019424